Celltrion Inc. (068270)

Overview

Celltrion, Inc., established in 2002 and based in Incheon, South Korea, operates at the forefront of biotechnology, specializing in the development and production of protein-based pharmaceuticals. The company's scope covers treatments across various medical fields including oncology, leveraging state-of-the-art biotechnological processes to market biosimilars and generic pharmaceuticals. In response to global health needs, Celltrion has extended its product range to include Covid-19 test kits, marking its presence in the diagnostic segment in addition to its therapeutic solutions. Through a combination of in-house development and strategic partnerships, Celltrion continues to innovate in the biosimilar space, contributing significantly to modern healthcare.

Products and Services

• CT-P39

  Currently in phase 3 clinical trials, CT-P39 is an antibody biosimilar aiming to provide treatment options for patients suffering from asthma and urticaria. Its development underscores Celltrion's commitment to addressing respiratory and allergic conditions.

• CT-P41

  CT-P41 is a biosimilar candidate in phase 3 clinical trials, designed for the treatment of osteoporosis and bone loss. This reflects the company’s endeavor to combat musculoskeletal diseases that affect millions globally.

• CT-P42

  In phase 3 clinical trials, CT-P42 represents Celltrion's efforts in the field of ophthalmology, specifically for diabetic macular edema. This underscores the company's focus on addressing complications arising from diabetes through innovative treatment options.

• CT-P43

  CT-P43 is in phase 3 clinical trials for the treatment of psoriasis, Crohn's disease, and ulcerative colitis, highlighting Celltrion's investment in solutions for autoimmune and inflammatory conditions. This displays the company’s dedication to improving the quality of life for patients with chronic conditions.

• CT-P47

  Targeting rheumatoid arthritis, CT-P47 is another of Celltrion's phase 3 clinical trial candidates, aimed at addressing autoimmune disorders. This biologic represents Celltrion's contribution towards offering more treatment options for rheumatoid arthritis patients.

• CT-P53

  CT-P53 is undergoing phase 3 clinical trials for the treatment of multiple sclerosis. This demonstrates Celltrion's commitment to neurology and tackling complex neurological disorders with advanced biotechnological approaches.

• Covid-19 Test Kits

  In response to the global pandemic, Celltrion expanded its portfolio to include Covid-19 test kits, providing essential diagnostic tools to help combat the spread of the virus. This initiative illustrates the company's adaptive response to emerging global health crises.